Alteogen secures European patent approval for ALT-B4, gaining exclusive rights

Biopharmaceutical company Alteogen has secured a significant step towards exclusive rights in Europe with the European Patent Office's (EPO) intention to grant a patent for its proprietary recombinant human hyaluronidase, ALT-B4.

The EPO's decision signifies that the patent has successfully passed examination, and the office has officially notified Alteogen of its intent to register the patent. This development is a crucial milestone for the company, paving the way for the finalization of patent registration through subsequent procedures in individual European countries.

ALT-B4 is a key component of Alteogen's technological platform, designed to enhance the absorption and efficacy of various therapeutic drugs. The hyaluronidase enzyme works by breaking down hyaluronic acid in the subcutaneous tissue, thereby increasing the permeability and allowing for greater diffusion of co-administered medications.

This European patent is expected to bolster Alteogen's intellectual property portfolio and strengthen its market position. The company aims to leverage this exclusive right to pursue partnerships and licensing agreements, potentially accelerating the development and commercialization of therapies utilizing ALT-B4 across Europe.